BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The findings of this study, the first in Côte d'Ivoire, have confirmed the importance of monitoring the level of BCR::ABL1IS transcript at 3 months following an imatinib therapy in patients with CP–CML.